Premium
Development and standardization of methodology for diagnosis and detection of response to chemotherapy in patients with colorectal cancer
Author(s) -
Assis Jéssica Vieira,
Coutinho Lucélia,
Oliveira Matheus,
Cruz Renata,
Grenfell Rafaella
Publication year - 2017
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.31.1_supplement.942.11
Subject(s) - colorectal cancer , medicine , cxcr4 , cancer research , folfiri , folfox , antigen , cancer , oncology , biology , chemokine , immunology , oxaliplatin , inflammation
Colorectal cancer (CRC) is a heterogeneous disease. Subtyping in gene expression is recognized as a relevant criterion for classification of the disease, but its clinical usefulness is hampered by the lack of standard and methodology to be used between the clinical studies and analyze the responsiveness of each patient to the chemotherapeutic treatment. CXCR4 (CD184) when highly expressed generates proliferation and cell survival, angiogenesis and metastatic tumor migration. When the CD26 gene is less expressed, there is a decrease in local chemokine levels, thereby controlling the tumor in situ. Patients responsive to 5‐FU, FOLFOX and FOLFIRI present a significant reduction in CXCR4 expression and progressive increase of CD26, where the inverse ratio is seen in nonresponsive patients. Thus, in order to standardize high sensitivity methodology for diagnosis and prognosis, we developed the use of technology of detection of circulating antigens through the use of nanotechnology associated with antibodies. Thus, following in vitro methodology, anti‐CXCR4 (CD184) and anti‐CD26 pAbs were due to producing clones of IgM or IgG subtypes for each marker, since the difference between the expressions of such genes suggests an interesting imbalance, generating a possible response. After standardization of tumor induction in nude mice, HT‐29 cells (mutation at codon 273 of the p53 gene) were performed, four inoculations of these proteins were carried out and throughout the production process, immunoenzymatic assays were performed for identification and selection of clones Positive. The purified antibodies were tested to SDS‐PAGE and Western Blotting for confirmation of specificity. Thereafter, the HT‐29 cells removed from mice will be labeled to verify the expression of CXCR4 and CD26 on their surfaces from the inoculated pAb and thereafter, tissues from patients at different stages of the disease will also be labeled. We thus sought, in clinical cases, to assist the medical team in the decision of the treatment leading the patient to the surgical intervention and/or the conventional chemotherapies. Support or Funding Information Financial support: Fiocruz, PDTIS, FINEP (Brazil).